Last reviewed · How we verify
CBG002 CAR-T Cell Suspension
At a glance
| Generic name | CBG002 CAR-T Cell Suspension |
|---|---|
| Sponsor | Carbiogene Therapeutics Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBG002 CAR-T Cell Suspension CI brief — competitive landscape report
- CBG002 CAR-T Cell Suspension updates RSS · CI watch RSS
- Carbiogene Therapeutics Co. Ltd. portfolio CI